Erratum: The emerging safety profile of JAK inhibitors in rheumatic disease

Nature Reviews Rheumatology 13, 234–243 (2017) In 'Gastrointestinal perforation' of the 'Adverse effects of JAK inhibitors' section, in the sentence “In patients with RA receiving baricitinib, two cases of gastrointestinal perforations were reported (an incidence of 5 cases per 1,000 patient-years in the development program)” the incidence should have been 0.